Evidence map›Paper›PMID 30410046›Full record

ArticleNature communications2018

Structural basis for the second step of group II intron splicing.

Russell T Chan, Jessica K Peters, Aaron R Robart, Timothy Wiryaman, Kanagalaghatta R Rajashankar, Navtej Toor

Abstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. RNA Triple Helices: From Structures and Mechanisms to Therapeutic Targets.International journal of biological sciences · 2026
    Review
  2. Review
  3. Computational De Novo Design of Group II Introns Yields Highly Active Ribozymes.Chembiochem : a European journal of chemical biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Retroelement origins of pre-mRNA splicing.Wiley interdisciplinary reviews. RNA · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Russell T ChanDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Jessica K PetersDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Aaron R RobartDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Timothy WiryamanDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Kanagalaghatta R RajashankarNE-CAT and Department of Chemistry and Chemical Biology, Cornell University, Argonne National Laboratory, Argonne, IL, 60439, USA.
Navtej ToorDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA. ntoor@ucsd.edu.ORCID http://orcid.org/0000-0002-6134-163X

Funding

GENETIC MECHANISMS AND REGULATIONT32GM007240 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMPTON, RANDOLPH Y. · 1985 to 2019
$23.8M
Overall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3M
MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008326 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOMIVES, ELIZABETH A. · 1989 to 2020
$7.5M
Structural Biology of RNA SplicingR01GM102216 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TOOR, NAVTEJ SINGH · 2012 to 2016
$1.5M
Structural Biology of Retrotransposition (Equipment Supplement)R01GM123275 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TOOR, NAVTEJ SINGH · 2017 to 2020
$1.3M
NIGMS NIH HHS P41 GM103403NIGMS NIH HHS R01 GM102216NIGMS NIH HHS R01 GM123275NIGMS NIH HHS T32 GM007240NIGMS NIH HHS T32 GM008326U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 1R01GM123275U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 5R01GM102216
6 · The paper itself

Abstract

The group II intron and the spliceosome share a common active site architecture and are thought to be evolutionarily related. Here we report the 3.7 Å crystal structure of a eukaryotic group II intron in the lariat-3' exon form, immediately preceding the second step of splicing, analogous to the spliceosomal P complex. This structure reveals the location of the intact 3' splice site within the catalytic core of the group II intron. The 3'-OH of the 5' exon is positioned in close proximity to the 3' splice site for nucleophilic attack and exon ligation. The active site undergoes conformational rearrangements with the catalytic triplex having different configurations before and after the second step of splicing. We describe a complete model for the second step of group II intron splicing that incorporates a dynamic catalytic triplex being responsible for creating the binding pocket for 3' splice site capture.

Indexed as

Nucleic Acid ConformationBase SequenceBiocatalysisExonsIntronsModels, MolecularMutagenesisMutationPhaeophyceaeRNA Splice SitesRNA SplicingSoftwareSpliceosomesRNA Splice Sites

Identifiers

PMID30410046
PMCPMC6224600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.